Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of ulinastatin in preparation of drugs for treating multiple sclerosis

A multiple sclerosis, ulinastatin technology, applied in the field of medicine, can solve the problems of limited drugs for multiple sclerosis, increased neuron loss, high price, etc. Effect

Inactive Publication Date: 2016-07-20
GUANGDONG TECHPOOL BIO-PHARMA CO LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Current evidence-based medicines for multiple sclerosis are limited and expensive
At present, MS drug therapy is mainly aimed at anti-inflammation and immune regulation. The standard classic treatment in the acute phase is high-dose hormone pulse therapy, which is often accompanied by serious side effects such as infection, gonadal suppression, and tumors, and inhibits endogenous brain protection pathways. , increasing neuronal loss
In addition, the vast majority still use adrenal glucocorticoids, immunosuppressants and other treatments, which have limited effects and large side effects, especially obvious hepatotoxicity, nephrotoxicity and teratogenicity, so it is necessary to find safer and more effective therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of ulinastatin in preparation of drugs for treating multiple sclerosis
  • Use of ulinastatin in preparation of drugs for treating multiple sclerosis
  • Use of ulinastatin in preparation of drugs for treating multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1, ulinastatin injection

[0021] Preparation method: Take 100 million units of ulinastatin aqueous solution sterilized by filtration, add 20 grams of mannitol to dissolve, add citrate buffer solution to adjust pH to neutral, add water for injection to 1000 ml, add sodium chloride to adjust isotonicity , sterile filtered, and packed in 500 vials.

Embodiment 2

[0022] Embodiment 2, ulinastatin injection

[0023] Preparation method: Take 100 million units of filtered sterilized ulinastatin aqueous solution, add 20 grams of mannitol to dissolve, add citrate buffer to adjust pH to neutral, add water for injection to 2000 ml, add sodium chloride to adjust isotonicity , sterile filtered, and packed in 1000 vials, to get final product.

Embodiment 3

[0024] Embodiment 3, ulinastatin injection

[0025] Preparation method: Take 100 million units of ulinastatin aqueous solution sterilized by filtration, add 20 grams of mannitol to dissolve, add citrate buffer solution to adjust pH to neutral, add water for injection to 4000 ml, add sodium chloride to adjust isotonicity , sterile filtered, and packed in 2000 vials, to get final product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine and particularly discloses use of ulinastatin in the preparation of drugs for treating multiple sclerosis. It is proved herein that by treating a multiple sclerosis rat (EAE model) with ulinastatin, weight reduction can be significantly reduced for the EAE rat, death rate of the EAE rat can be significantly reduced, onset latency can be significantly delayed, and neural protection can be achieved; in addition, ulinastatin can also increase TGF-beta and IL-10 expression, restore the balance of Th1 / Th2 cell factors and relieve EAE process by reducing IL-2, IFN-gamma and TNF-alpha expression and can accelerate EAE recovery b adjusting apoptosis-promoting Bax and Fas proteins and inhibiting Bcl protein expression. The ulinastatin of the invention has low toxic and side effect, is high in safety, can protect heart, liver, kidney and lung, is low in cost and has a promising development prospect as a drug for treating multiple sclerosis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically discloses the use of ulinastatin in preparing medicine for treating multiple sclerosis. Background technique [0002] Ulinastatin is a broad-spectrum protease inhibitor, which belongs to human endogenous anti-inflammatory substances. It is mainly synthesized in the liver, metabolized by the kidneys and excreted in urine, and the low molecular weight components formed by its decomposition also have a strong inhibitory effect on hydrolytic enzymes. It has strong anti-inflammatory, immune regulation, microcirculation improvement, anti-shock, anti-ischemia and neuroprotective effects. In addition, studies have shown that ulinastatin has protective effects on the heart, liver, kidney, lung and other important organs of the human body. [0003] Chinese patent application 201010299506.9 discloses the use of ulinastatin for the preparation of drugs for the treatment of autoimmune ence...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/57A61K9/08A61K9/19A61K47/10A61P25/00
CPCA61K38/57A61K9/0019A61K9/08A61K9/19A61K47/10
Inventor 宋建东叶晓春孙明晖侯维静赵菁
Owner GUANGDONG TECHPOOL BIO-PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com